The paper's citation list
No. | The paper's citation list |
|---|
1 | PRO‐C3, liver fibrosis and CKD: The plot thickens. 2024;44:1126 doi: 10.1111/liv.15888 |
2 | Sinusoidal Cells in Liver Diseases. 2024;263 doi: 10.1016/B978-0-323-95262-0.00012-7 |
3 | Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity. 2024;46:7134 doi: 10.3390/cimb46070425 |
4 | Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management. 2025; doi: 10.37349/emed.2025.1001281 |
5 | Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease. 2024;4: doi: 10.20517/mtod.2024.42 |
6 | Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. 2025; doi: 10.1016/j.tem.2024.12.009 |
7 | Towards linking histological changes to liver viscoelasticity: a hybrid analytical-computational micromechanics approach. 2025;70:045005 doi: 10.1088/1361-6560/adaad3 |
8 | Effect of Donor Age and Liver Steatosis on Potential of Decellularized Liver Matrices to be used as a Platform for iPSC‐Hepatocyte Culture. 2024;13: doi: 10.1002/adhm.202302943 |
9 | Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease. 2025;31: doi: 10.3748/wjg.v31.i3.100393 |
